ALIVUS — Alivus Life Sciences Share Price
Last trade - 00:00- IN₹126.99bn
- IN₹121.84bn
- IN₹22.83bn
- 94
- 21
- 70
- 69
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5 | ||
| Price to Tang. Book | 5.04 | ||
| Price to Free Cashflow | 47.92 | ||
| Price to Sales | 5.58 | ||
| EV to EBITDA | 19.48 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 21.61% | ||
| Return on Equity | 17.92% | ||
| Operating Margin | 24.91% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 15,373.13 | 18,851.65 | 21,232.14 | 21,612.2 | 22,832.14 | n/a | n/a | 20.83% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +60.11 | +12.1 | +24.17 | +6.93 | +0.74 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as antifungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 23rd, 2011
- Public Since
- August 6th, 2021
- No. of Shareholders
- 156,183
- No. of Employees
- 2,014
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 122,537,052
- Address
- Glenmark House, MUMBAI, 400099
- Web
- https://www.alivus.com/
- Phone
- +91 2268297979
- Contact
- Rudalf Corriea
- Auditors
- Walker Chandiok & Co LLP
Upcoming Events for ALIVUS
Similar to ALIVUS
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 19:11 UTC, shares in Alivus Life Sciences are trading at IN₹1,036.30. This share price information is delayed by 15 minutes.
Shares in Alivus Life Sciences last closed at IN₹1,036.30 and the price had moved by +38.08% over the past 365 days. In terms of relative price strength the Alivus Life Sciences share price has outperformed the S&P BSE 100 Index by +30.07% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Alivus Life Sciences dividend yield is 2.17% based on the trailing twelve month period.
Last year, Alivus Life Sciences paid a total dividend of IN₹22.50, and it currently has a trailing dividend yield of 2.17%. We do not have any data on when Alivus Life Sciences is to next pay dividends.
We do not have data on when Alivus Life Sciences is to next pay dividends. The historic dividend yield on Alivus Life Sciences shares is currently 2.17%.
To buy shares in Alivus Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹1,036.30, shares in Alivus Life Sciences had a market capitalisation of IN₹126.99bn.
Here are the trading details for Alivus Life Sciences:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: ALIVUS
Based on an overall assessment of its quality, value and momentum Alivus Life Sciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alivus Life Sciences. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +12.77%.
As of the last closing price of IN₹1,036.30, shares in Alivus Life Sciences were trading -1.11% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alivus Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹1,036.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Alivus Life Sciences' directors